

# Roles of G-protein-coupled receptor dimerization

## From ontogeny to signalling regulation

Sonia Terrillon & Michel Bouvier<sup>+</sup>

Université de Montréal, Québec, Canada

**The classical idea that G-protein-coupled receptors (GPCRs) function as monomeric entities has been unsettled by the emerging concept of GPCR dimerization. Recent findings have indicated not only that many GPCRs exist as homodimers and heterodimers, but also that their oligomeric assembly could have important functional roles. Several studies have shown that dimerization occurs early after biosynthesis, suggesting that it has a primary role in receptor maturation. G-protein coupling, downstream signalling and regulatory processes such as internalization have also been shown to be influenced by the dimeric nature of the receptors. In addition to raising fundamental questions about GPCR function, the concept of dimerization could be important in the development and screening of drugs that act through this receptor class. In particular, the changes in ligand-binding and signalling properties that accompany heterodimerization could give rise to an unexpected pharmacological diversity that would need to be considered.**

Keywords: G-protein-coupled receptor function; heterodimerization; homodimerization; oligomerization; regulation

EMBO reports (2004) 5, 30–34. doi:10.1038/sj.embor.7400052

### Introduction

G-protein-coupled receptors (GPCRs) have classically been assumed to exist and function as monomeric entities, and the paradigms of ligand binding and signal transduction were based on this hypothesis. However, a growing body of biochemical and biophysical evidence indicates that some GPCRs can form both homodimers and heterodimers. Although their existence is now largely accepted (Angers *et al*, 2002; George *et al*, 2002), their functional importance remains more enigmatic and in some cases even controversial. The five stages of the GPCR life cycle that could be affected by dimerization are depicted in Fig 1. In this review, we focus our attention on the potential functional implications that have been proposed for GPCR dimerization at each of these stages, indicating, when possible, the aspects that will require additional studies before definitive conclusions can be drawn. Given that most current methods used do not strictly distinguish between dimers and larger oligomers, we

refer systematically to the term 'dimer' because it represents the minimal oligomeric arrangement.

### Ontogeny


GPCR biosynthesis and transport along the secretory pathway are poorly characterized, but their exit from the endoplasmic reticulum (ER) is a crucial step that controls their cell surface expression (Petaja-Repo *et al*, 2000). Only correctly folded receptors escape the ER quality-control system and are allowed to exit, whereas incompletely folded or misfolded proteins are retained and eventually degraded (Petaja-Repo *et al*, 2001). For many proteins, oligomeric assembly has an important function in ER quality control because it masks specific retention signals or hydrophobic patches that would otherwise retain the proteins in the ER (Reddy & Corley, 1998). For GPCRs, the necessity of dimerization for correct transport to the plasma membrane has been clearly shown for the metabotropic  $\gamma$ -aminobutyric acid b receptor (G<sub>b</sub>R), which is composed of two subunits G<sub>b</sub>R<sub>1</sub> and G<sub>b</sub>R<sub>2</sub> (Marshall *et al*, 1999). When expressed alone, G<sub>b</sub>R<sub>1</sub> is retained intracellularly as an immature protein because it has a carboxy-terminal ER retention motif (Margeta-Mitrovic *et al*, 2000), whereas G<sub>b</sub>R<sub>2</sub> reaches the cell surface but is not functional. Following their co-expression, heterodimerization masks the G<sub>b</sub>R<sub>1</sub> ER retention signal, allowing the proper targeting of a functional heterodimeric G<sub>b</sub>R to the plasma membrane. Although a general role for heterodimerization and/or homodimerization in GPCR quality control and ER export has not yet been established, studies using cellular fractionation and fluorescence or bioluminescence resonance energy transfer (FRET and BRET, respectively) have revealed that several GPCRs dimerize in the ER (Issafras *et al*, 2002; Overton & Blumer, 2002; Terrillon *et al*, 2003; Floyd *et al*, 2003). Consistent with the idea that GPCR dimerization occurs early in the secretory pathway is the observation that truncated mutants of vasopressin V<sub>2</sub>R (Zhu & Wess, 1998), D<sub>3</sub> dopamine (Karpa *et al*, 2000), GnRH gonadotropin-releasing hormone (Grosse *et al*, 1997) and CCR<sub>5</sub> chemokine (Benkirane *et al*, 1997; Shioda *et al*, 2001) receptors, as well as rhodopsin mutants (Colley *et al*, 1995) behave as dominant-negatives of their respective wild-type receptors by preventing their expression on the cell surface. As the physical interaction between wild-type and mutant receptors was confirmed by co-immunoprecipitation in some of these studies (Benkirane *et al*, 1997; Zhu & Wess, 1998; Karpa *et al*, 2000), the dominant-negative action was taken as evidence that early heterodimerization between wild-type and mutant receptors leads to their ER retention. For

Department of Biochemistry, Université de Montréal, C.P. 6128, succursale Centre-Ville, Montréal, Québec, Canada H3C 3J7

<sup>+</sup>Corresponding author. Tel: +1 514 343 6372; Fax: +1 514 343 2210;

E-mail: michel.bouvier@umontreal.ca

Submitted 13 August 2003; accepted 4 November 2003



**Fig 1** | Potential roles of G-protein-coupled receptor (GPCR) dimerization during the GPCR life cycle. (1) In some cases, dimerization has been shown to have a primary role in receptor maturation and allows the correct transport of GPCRs from the endoplasmic reticulum (ER) to the cell surface. (2) Once at the plasma membrane, dimers might become the target for dynamic regulation by ligand binding. (3) It has been proposed that GPCR heterodimerization leads to both positive (+) and negative (−) ligand binding cooperativity, as well as (4) potentiating (+)/attenuating (−) signalling or changing G-protein selectivity. (5) Heterodimerization can promote the co-internalization of two receptors after the stimulation of only one protomer. Alternatively, the presence of a protomer that is resistant to agonist-promoted endocytosis, within a heterodimer, can inhibit the internalization of the complex. G, G protein; L, ligand.

naturally occurring mutations this could have pathophysiological consequences. For example, it has been suggested that the loss of cell-surface expression of CCR<sub>5</sub> observed following its co-expression with the ER-retained CCR<sub>5</sub>Δ32 mutant contributes to the delayed onset of AIDS in HIV-infected patients that harbour a CCR<sub>5</sub>/CCR<sub>5</sub>Δ32 genotype (Benkirane *et al*, 1997). A series of rhodopsin mutants was also proposed to cause retinal degeneration in *Drosophila* by interfering with the maturation of the wild-type photoreceptor (Colley *et al*, 1995).

### Ligand-promoted regulation

A role for dimerization in GPCR ontogeny does not exclude the possibility that, once the receptor has reached the cell surface, its oligomeric state could be dynamically regulated. Whether receptor activation can promote or inhibit dimerization and/or favour exchanges between protomers is a central question with wide implications for the mechanisms of receptor activation and regulation. Unfortunately, no general consensus has yet been established. Whereas several studies suggest that ligand binding can regulate the dimer by either promoting (Rodriguez-Frade *et al*, 1999; Angers *et al*, 2000; Rocheville *et al*, 2000a,b; Cornea *et al*, 2001; Horvat *et al*, 2001; Kroeger *et al*, 2001; Wurch *et al*, 2001; Patel *et al*, 2002; Zhu *et al*, 2002; Hunzicker-Dunn *et al*, 2003; Roess & Smith, 2003) or inhibiting (Gines *et al*, 2000; Cheng & Miller, 2001; Latif *et al*, 2002) its formation, many others conclude that homodimerization and heterodimerization are constitutive processes that are not modulated by ligand binding (Overton & Blumer, 2000; Ayoub *et al*, 2002; Issafras *et al*, 2002; Jensen *et al*, 2002; Babcock *et al*, 2003; Canals *et al*, 2003; Dinger *et al*, 2003;

Floyd *et al*, 2003; Guo *et al*, 2003; Stanasila *et al*, 2003; Terrillon *et al*, 2003; Trettel *et al*, 2003). Although such discrepancies might reflect intrinsic differences in the behaviour of the individual receptors considered in each study, they might also result from interpretational difficulties linked to the techniques used. In many cases, the extent of receptor co-immunoprecipitation, determined by western blot analysis, was used to assess the effects of ligands on the dimerization state. Unfortunately, such approaches are not highly quantitative, and changes in the immunoreactivity detected could result from agonist-induced conformational changes that alter epitope recognition rather than from varying amounts of receptor dimers. In other cases, ligand-induced increases or decreases in BRET or FRET were interpreted as ligand-regulated dimerization. However, given that the efficacy of BRET and FRET is highly dependent on the relative distance and orientation between the donor and acceptor fluorophores, ligand-promoted changes in energy transfer could reflect either a modulation of the dimerization process or changes in the conformation of pre-existing dimers. Additional experimental approaches will be required to determine unambiguously whether or not the dimerization process is subjected to ligand-promoted regulation.

In any case, the structural data available strongly suggest that at least some GPCRs can form dimers in the absence of ligand stimulation. For instance, crystallization of the extracellular amino-terminal ligand-binding domains of the metabotropic glutamate receptor, mGluR<sub>1</sub> (Kunishima *et al*, 2000), and the Wnt receptor, frizzled (Dann *et al*, 2001), revealed that they exist as dimers in the absence of their ligands. More recently, Palczewski and co-workers used

atomic force microscopy to show that rhodopsin and opsin form constitutive dimers in dark-adapted native retinal membranes (Fotiadis *et al*, 2003; Liang *et al*, 2003).

### Pharmacological diversity

The concept that GPCR heterodimerization could have a role in pharmacological diversity was first indicated by studies on the  $\delta$ - and  $\kappa$ -opioid receptors (Jordan & Devi, 1999). Co-expression of both receptors led to the formation of a stable heterodimer with a very low affinity for either the  $\delta$ - or the  $\kappa$ -selective ligand alone. However, high affinity was restored following the combination of the two ligands, suggesting the occurrence of positive cooperativity. Although the direct link between heterodimerization itself and the changes in pharmacological properties has not been formally established, positive or negative ligand-binding cooperativity that occurs after receptor co-expression has been interpreted as resulting from receptor heterodimerization for many other GPCRs. These include the metabotropic GbR GbR<sub>1</sub>/GbR<sub>2</sub> (Galvez *et al*, 2001), opioid  $\delta/\mu$  (Gomes *et al*, 2000), muscarinic m<sub>2</sub>/m<sub>3</sub> (Maggio *et al*, 1999), somatostatin SSTR<sub>5</sub>/dopamine D<sub>2</sub> (Rocheville *et al*, 2000a) and adenosine A<sub>2A</sub>/dopamine D<sub>1</sub> (Franco *et al*, 2000) receptors. If this is a general phenomenon, such heterodimerization between pharmacologically distinct receptors could underlie a level of pharmacological diversity that would have far-reaching implications for drug development. In particular, it could provide new opportunities for the development of more selective compounds that would target specific heterodimers without affecting the individual protomers (George *et al*, 2002). Obviously, testing all possible combinations from existing GPCRs represents a daunting task that cannot be achieved with the current methods. So, establishing the rules that dictate the selectivity of interactions between receptors and determining their occurrence in native tissues will be essential before heterodimerization can be systematically incorporated into drug screening campaigns.

### Signal transduction

The first convincing evidence that GPCR dimerization has a crucial function in signal transduction came from studies on the GbR. Even though GbR<sub>1</sub> harbours the binding site for  $\gamma$ -aminobutyric acid (GABA), its co-expression with GbR<sub>2</sub> was found to be essential for the formation of a receptor that can couple functionally to the G-protein signalling cascade (Margeta-Mitrovic *et al*, 2000; Galvez *et al*, 2001). This is not just because GbR<sub>2</sub> is required for the expression of GbR<sub>1</sub> on the cell surface (see above), as a mutant form of GbR<sub>1</sub> that lacks its ER retention signal and can reach the cell surface on its own still requires GbR<sub>2</sub> for functional activity (Margeta-Mitrovic *et al*, 2000). Using a combination of chimeric receptor constructs of GbR<sub>1</sub> and GbR<sub>2</sub>, Pin and colleagues proposed a transactivation model in which GbR<sub>1</sub> binds GABA while GbR<sub>2</sub> activates the G protein (Galvez *et al*, 2001). More recently, it has also been proposed that heterodimerization is obligatory for the formation of functional taste receptors. Indeed, sweet (Nelson *et al*, 2001) and L-amino-acid (Nelson *et al*, 2002) taste responses were strictly dependent on the co-expression of T<sub>1</sub>R<sub>3</sub> and either T<sub>1</sub>R<sub>2</sub> or T<sub>1</sub>R<sub>1</sub>, respectively. Even if these three cases are the only ones for which obligatory heterodimerization has been firmly established, such oligomerization has often been invoked to explain the changes in signalling properties that result from the co-expression of distinct receptors. Signalling potentiation resulting from heterodimerization has been suggested for the opioid  $\delta/\kappa$  (Jordan & Devi, 1999), opioid  $\delta/\mu$  (Gomes *et al*, 2000), chemokine CCR<sub>5</sub>/CCR<sub>2</sub>

(Mellado *et al*, 2001), somatostatin SSTR<sub>5</sub>/dopamine D<sub>2</sub> (Rocheville *et al*, 2000a), angiotensin AT<sub>1</sub>/bradykinin B<sub>2</sub> (AbdAlla *et al*, 2000) and metabotropic glutamate 1 $\alpha$ /adenosine A<sub>1</sub> (Ciruela *et al*, 2001) receptors, whereas signal attenuation has been described for the somatostatin SSTR<sub>2A</sub>/SSTR<sub>3</sub> (Pfeiffer *et al*, 2001), adenosine A<sub>1</sub>/dopamine D<sub>1</sub> (Gines *et al*, 2000), angiotensin AT<sub>1</sub>/bradykinin B<sub>2</sub> (AbdAlla *et al*, 2000) and yeast  $\alpha$ -mating factor wild-type/mutant (Overton & Blumer, 2000) receptors. Heterodimerization has also been proposed to promote changes in the selectivity of some GPCRs towards the different G-protein subfamilies (G<sub>s</sub>, G<sub>i</sub>, G<sub>q</sub> and G<sub>12</sub>). In particular, a loss of G<sub>i</sub> coupling has been reported following co-expression of  $\mu$ - and  $\delta$ -opioid receptors (George *et al*, 2000; Charles *et al*, 2003) and in cells that co-express CCR<sub>5</sub> and CCR<sub>2</sub> chemokine receptors (Mellado *et al*, 2001). Although the formation of heterodimers was confirmed in all the above studies by either co-immunoprecipitation or resonance-energy-transfer approaches, cross-talk regulation involving downstream components of the individual signalling pathways activated by each receptor cannot be formally excluded. So the contribution of heterodimerization to the observed phenotypes cannot be proved unambiguously.

The classical model of G-protein activation is based on the premise that one receptor interacts with one heterotrimeric G protein at a time. However, this concept should be re-examined in the context of GPCR dimerization. Does one dimer activate one or two G proteins? Structural studies of the receptor–G-protein interface have led to the identification of several points of contact between the G protein and the receptor on both  $\alpha$ - and  $\beta\gamma$ -subunits (Hamm, 2001). However, the crystallographic structure of rhodopsin revealed that its cytoplasmic surface is too small to accommodate these points of contact simultaneously. This led to the proposition that two receptor molecules might be necessary to satisfy the binding requirements of a single G protein (Hamm, 2001; Liang *et al*, 2003). An elegant reconstitution study recently supported this idea. Chemical cross-linking followed by size-exclusion chromatography, mass spectroscopy and neutron scattering measurements demonstrated clearly that the complex formed between the purified, activated leukotriene B<sub>4</sub> receptor BLT<sub>1</sub> and G $\alpha_{12}\beta_1\gamma_2$  corresponds to a pentameric assembly of one heterotrimeric G protein and one dimeric receptor (Baneres & Parello, 2003). It remains to be determined whether this arrangement of one GPCR dimer interacting with a single heterotrimeric G protein is the functional complex in cells.

### Internalization

Several recent studies have suggested that heterodimerization could affect agonist-promoted GPCR endocytosis, a well-characterized process classically involved in signal attenuation. For many documented heterodimers, stimulation of only one of the protomers was sufficient to promote co-internalization of the two receptors. These include: SSTR<sub>1</sub>/SSTR<sub>5</sub> somatostatin (Rocheville *et al*, 2000b),  $\delta$ -opioid/ $\beta_2$  adrenergic ( $\beta_2$ AR; Jordan *et al*, 2001),  $\alpha_{2A}$ / $\beta_1$  adrenergic (Xu *et al*, 2003),  $\alpha_{1A}$ / $\alpha_{1B}$  adrenergic (Stanasila *et al*, 2003), SSTR<sub>2A</sub> somatostatin/ $\mu$  opioid (Pfeiffer *et al*, 2002) and A<sub>2A</sub> adenosine/D<sub>2</sub> dopamine (Hillion *et al*, 2002) receptors. In the last two cases, the co-internalization was also associated with a cross-desensitization of the signalling activities. By contrast, receptors that do not undergo efficient agonist-promoted endocytosis were found to act as dominant-negatives for endocytosis-prone receptors after heterodimerization. For example, the  $\kappa$ -opioid receptor inhibited the endocytosis of both  $\delta$ -opioid receptors (Jordan & Devi, 1999) and the  $\beta_2$ AR (Jordan *et al*, 2001), whereas the  $\beta_1$ AR



prevented the agonist-promoted internalization of the  $\beta_2$ AR (Lavoie *et al.*, 2002). In some of these studies, a non-specific effect on the endocytosis of all GPCRs was ruled out by showing that the internalization of non-related GPCRs was not affected (Stanasila *et al.*, 2003). Although of significant potential interest, the physiological consequences of these observations on the regulation of GPCR desensitization/resensitization cycles remain to be determined.

### Physiological relevance

Until now, heterologous expression systems have been the preferred models to study the functional consequences of GPCR dimerization, which raises the question of physiological relevance. For instance, the artificial co-expression of receptors that are never expressed together in the same cells *in vivo* could lead to erroneous conclusions. In addition, although great care has been taken in many studies to maintain expression levels within physiological ranges, the high expression levels that are sometimes achieved with these systems could lead to spurious interactions. This possibility has been elegantly illustrated in a recent study, which reported that  $\delta$ -opioid receptors and  $\beta_2$ AR could form heterodimers but only when expressed at high levels (Ramsay *et al.*, 2002). Nevertheless, the potential physiological importance of heterodimerization is supported by studies in cells that endogenously co-express the GPCRs under consideration. For example, the synergistic binding or signalling documented in heterologous expression systems between the  $\delta$ - and  $\mu$ -opioid (Gomes *et al.*, 2000), the metabotropic glutamate<sub>1a</sub> and adenosine A<sub>1</sub> (Ciruela *et al.*, 2001) as well as the angiotensin AT<sub>1</sub> and the bradykinin B<sub>2</sub> (AbdAlla *et al.*, 2000) receptors were also observed in neuroblastoma cells, cortical neurons and smooth muscle cells, respectively. More recently, the blockade of either the AT<sub>1</sub> receptor or the  $\beta_2$ AR with selective antagonists was found to inhibit the signalling of both receptors simultaneously in freshly isolated mouse cardiomyocytes (Barki-Harrington *et al.*, 2003), a phenomenon linked to the ability of the two receptors to heterodimerize.

### Conclusion

Although first met with healthy scepticism, the concept that GPCRs can exist as dimeric entities is now largely accepted. As summarized here, mounting evidence now suggests that the homodimerization and heterodimerization of GPCRs could be important in aspects of their biology that range from ontogeny to the regulation of their pharmacological and signalling properties. However, many more studies will be required for the following: (1) to establish the general physiological importance of dimerization in native systems, (2) to identify the dimerization interface and elucidate the three-dimensional organization of the dimers, (3) to find out the rules that dictate the selectivity of interactions between receptors, (4) to determine the stoichiometry of interaction between receptors and their partner proteins, and (5) to assess whether higher-order oligomeric complexes that include more than two receptors exist. Gathering this information will be a challenging task that will require the further development of innovative approaches permitting both the study of protein-protein interactions in living cells and the determination of the three-dimensional structures of transmembrane proteins.

### ACKNOWLEDGEMENTS

We are grateful to M. Lagaeé for critical reading of the manuscript. M.B. holds a Canada Research Chair in signal transduction and molecular pharmacology. Work in the Bouvier laboratory is supported by the Canadian Institute for Health Research.

### REFERENCES

- AbdAlla S, Lother H, Quitterer U (2000) AT<sub>1</sub>-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. *Nature* **407**: 94–98
- Angers S, Salahpour A, Joly E, Hilalret S, Chelsky D, Dennis M, Bouvier M (2000) Detection of  $\beta_2$ -adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). *Proc Natl Acad Sci USA* **97**: 3684–3689
- Angers S, Salahpour A, Bouvier M (2002) Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. *Annu Rev Pharmacol Toxicol* **42**: 409–435
- Ayoub MA, Couturier C, Lucas-Meunier E, Angers S, Fossier P, Bouvier M, Jockers R (2002) Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. *J Biol Chem* **277**: 21522–21528
- Babcock GJ, Farzan M, Sodroski J (2003) Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor. *J Biol Chem* **278**: 3378–3385
- Banerres JL, Parello J (2003) Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B<sub>4</sub> receptor BLT1 and the G-protein. *J Mol Biol* **329**: 815–829
- Barki-Harrington L, Luttrell LM, Rockman HA (2003) Dual inhibition of  $\beta$ -adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction *in vivo*. *Circulation* **108**: 1611–1618
- Benkirane M, Jin DY, Chun RF, Koup RA, Jeang KT (1997) Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by Ccr5832. *J Biol Chem* **272**: 30603–30606
- Canals M *et al.* (2003) Adenosine A<sub>2A</sub>-dopamine D<sub>2</sub> receptor-receptor heteromerization. Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. *J Biol Chem* **278**: 46741–46749
- Charles AC, Mostovskaya N, Asas K, Evans CJ, Dankovich ML, Hales TG (2003) Coexpression of  $\delta$ -opioid receptors with  $\mu$  receptors in GH3 cells changes the functional response to  $\mu$  agonists from inhibitory to excitatory. *Mol Pharmacol* **63**: 89–95
- Cheng ZJ, Miller LJ (2001) Agonist-dependent dissociation of oligomeric complexes of G protein-coupled cholecystokinin receptors demonstrated in living cells using bioluminescence resonance energy transfer. *J Biol Chem* **276**: 48040–48047
- Ciruela F *et al.* (2001) Metabotropic glutamate 1 $\alpha$  and adenosine A<sub>1</sub> receptors assemble into functionally interacting complexes. *J Biol Chem* **276**: 18345–18351
- Colley NJ, Cassill JA, Baker EK, Zuker CS (1995) Defective intracellular transport is the molecular basis of rhodopsin-dependent dominant retinal degeneration. *Proc Natl Acad Sci USA* **92**: 3070–3074
- Cornea A, Janovick JA, Maya-Nunez G, Conn PM (2001) Gonadotropin-releasing hormone receptor microaggregation. rate monitored by fluorescence resonance energy transfer. *J Biol Chem* **276**: 2153–2158
- Dann CE, Hsieh JC, Rattner A, Sharma D, Nathans J, Leahy DJ (2001) Insights into Wnt binding and signalling from the structures of two frizzled cysteine-rich domains. *Nature* **412**: 86–90
- Dinger MC, Bader JE, Kobor AD, Kretschmar AK, Beck-Sickinger AG (2003) Homodimerization of neuropeptide Y receptors investigated by fluorescence resonance energy transfer in living cells. *J Biol Chem* **278**: 10562–10571
- Floyd DH, Geva A, Bruinsma SP, Overton MC, Blumer KJ, Baranski TJ (2003) C5a receptor oligomerization. II. Fluorescence resonance energy transfer studies of a human G protein-coupled receptor expressed in yeast. *J Biol Chem* **278**: 35354–35361
- Fotiadis D, Liang Y, Filipek S, Saperstein DA, Engel A, Palczewski K (2003) Atomic-force microscopy: rhodopsin dimers in native disc membranes. *Nature* **421**: 127–128
- Franco R *et al.* (2000) Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. *Neuropsychopharmacology* **23**: S50–S59
- Galvez T, Duthey B, Kniazeff J, Blahos J, Rovelli G, Bettler B, Prezeau L, Pin JP (2001) Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA<sub>B</sub> receptor function. *EMBO J* **20**: 2152–2159
- George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, O'Dowd BF (2000) Oligomerization of  $\mu$ - and  $\delta$ -opioid receptors. Generation of novel functional properties. *J Biol Chem* **275**: 26128–26135
- George SR, O'Dowd BF, Lee SP (2002) G-protein-coupled receptor oligomerization and its potential for drug discovery. *Nature Rev Drug Discov* **1**: 808–820
- Gines S *et al.* (2000) Dopamine D<sub>1</sub> and adenosine A<sub>1</sub> receptors form functionally interacting heteromeric complexes. *Proc Natl Acad Sci USA* **97**: 8606–8611
- Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA (2000) Heterodimerization of  $\mu$  and  $\delta$  opioid receptors: a role in opiate synergy. *J Neurosci* **20**: RC110

- Grosse R, Schoneberg T, Schultz G, Gudermann T (1997) Inhibition of gonadotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. *Mol Endocrinol* **11**: 1305–1318
- Guo W, Shi L, Javitch JA (2003) The fourth transmembrane segment forms the interface of the dopamine D<sub>2</sub> receptor homodimer. *J Biol Chem* **278**: 4385–4388
- Hamm HE (2001) How activated receptors couple to G proteins. *Proc Natl Acad Sci USA* **98**: 4819–4821
- Hillion J *et al* (2002) Coaggregation, cointernalization, and codesensitization of adenosine A<sub>2A</sub> receptors and dopamine D<sub>2</sub> receptors. *J Biol Chem* **277**: 18091–18097
- Horvat RD, Roess DA, Nelson SE, Barisas BG, Clay CM (2001) Binding of agonist but not antagonist leads to fluorescence resonance energy transfer between intrinsically fluorescent gonadotropin-releasing hormone receptors. *Mol Endocrinol* **15**: 695–703
- Hunzicker-Dunn M, Barisas G, Song J, Roess DA (2003) Membrane organization of luteinizing hormone receptors differs between actively signaling and desensitized receptors. *J Biol Chem* **278**: 42744–42749
- Issafras H, Angers S, Bulenger S, Blanpain C, Parmentier M, Labbe-Jullie C, Bouvier M, Marullo S (2002) Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. *J Biol Chem* **277**: 34666–34673
- Jensen AA, Hansen JL, Sheikh SP, Brauner-Osborne H (2002) Probing intermolecular protein–protein interactions in the calcium-sensing receptor homodimer using bioluminescence resonance energy (BRET). *Eur J Biochem* **269**: 5076–5087
- Karpa KD, Lin R, Kabbani N, Levenson R (2000) The dopamine D<sub>3</sub> receptor interacts with itself and the truncated D<sub>3</sub> splice variant D<sub>3</sub>nf: D<sub>3</sub>-D<sub>3</sub>nf interaction causes mislocalization of D<sub>3</sub> receptors. *Mol Pharmacol* **58**: 677–683
- Kroeger KM, Hanyaloglu AC, Seeber RM, Miles LE, Eidne KA (2001) Constitutive and agonist-dependent homo-oligomerization of the thyrotropin-releasing hormone receptor. Detection in living cells using bioluminescence resonance energy transfer. *J Biol Chem* **276**: 12736–12743
- Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H, Morikawa K (2000) Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. *Nature* **407**: 971–977
- Latif R, Graves P, Davies TF (2002) Ligand-dependent inhibition of oligomerization at the human thyrotropin receptor. *J Biol Chem* **277**: 45059–45067
- Lavoie C *et al* (2002)  $\beta$ 1/ $\beta$ 2-adrenergic receptor heterodimerization regulates  $\beta$ 2-adrenergic receptor internalization and ERK signaling efficacy. *J Biol Chem* **277**: 35402–35410
- Liang Y, Fotiadis D, Filipek S, Saperstein DA, Palczewski K, Engel A (2003) Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. *J Biol Chem* **278**: 21655–21662
- Maggio R, Barbier P, Colelli A, Salvadori F, Demontis G, Corsini GU (1999) G protein-linked receptors: pharmacological evidence for the formation of heterodimers. *J Pharmacol Exp Ther* **291**: 251–257
- Margeta-Mitrovic M, Jan YN, Jan LY (2000) A trafficking checkpoint controls GABA<sub>B</sub> receptor heterodimerization. *Neuron* **27**: 97–106
- Marshall FH, Jones KA, Kaupmann K, Bettler B (1999) GABA<sub>B</sub> receptors—the first 7TM heterodimers. *Trends Pharmacol Sci* **20**: 396–399
- Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, Fernandez S, Martin de Ana A, Jones DR, Toran JL, Martinez A (2001) Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. *EMBO J* **20**: 2497–2507
- Nelson G, Hoon MA, Chandrashekar J, Zhang Y, Ryba NJ, Zuker CS (2001) Mammalian sweet taste receptors. *Cell* **106**: 381–390
- Nelson G, Chandrashekar J, Hoon MA, Feng L, Zhao G, Ryba NJ, Zuker CS (2002) An amino-acid taste receptor. *Nature* **416**: 199–202
- Overton MC, Blumer KJ (2000) G-protein-coupled receptors function as oligomers *in vivo*. *Curr Biol* **10**: 341–344
- Overton MC, Blumer KJ (2002) The extracellular N-terminal domain and transmembrane domains 1 and 2 mediate oligomerization of a yeast G protein-coupled receptor. *J Biol Chem* **277**: 41463–41472
- Patel RC *et al* (2002) Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. *Proc Natl Acad Sci USA* **99**: 3294–3299
- Petaja-Repo UE, Hogue M, Laperriere A, Walker P, Bouvier M (2000) Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human  $\delta$  opioid receptor. *J Biol Chem* **275**: 13727–13736
- Petaja-Repo UE, Hogue M, Laperriere A, Bhalla S, Walker P, Bouvier M (2001) Newly synthesized human  $\delta$  opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome. *J Biol Chem* **276**: 4416–4423
- Pfeiffer M, Koch T, Schroder H, Klutznay M, Kirscht S, Kreienkamp HJ, Holtt V, Schulz S (2001) Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of Sst<sub>1</sub> receptor function by heterodimerization with Sst<sub>2A</sub>. *J Biol Chem* **276**: 14027–14036
- Pfeiffer M, Koch T, Schroder H, Laugsch M, Holtt V, Schulz S (2002) Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. *J Biol Chem* **277**: 19762–19772
- Ramsay D, Kellett E, McVey M, Rees S, Milligan G (2002) Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. *Biochem J* **365**: 429–440
- Reddy PS, Corley RB (1998) Assembly, sorting, and exit of oligomeric proteins from the endoplasmic reticulum. *BioEssays* **20**: 546–554
- Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC (2000a) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. *Science* **288**: 154–157
- Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC (2000b) Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. *J Biol Chem* **275**: 7862–7869
- Rodriguez-Frade JM, Vila-Coro AJ, de Ana AM, Albar JP, Martinez A, Mellado M (1999) The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2. *Proc Natl Acad Sci USA* **96**: 3628–3633
- Roess DA, Smith SM (2003) Self-association and raft localization of functional luteinizing hormone receptors. *Biol Reprod* **69**: 1765–1770
- Shioda T, Nakayama EE, Tanaka Y, Xin X, Liu H, Kawana-Tachikawa A, Kato A, Sakai Y, Nagai Y, Iwamoto A (2001) Naturally occurring deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface trafficking of CCR5. *J Virol* **75**: 3462–3468
- Stanasila L, Perez JB, Vogel H, Cotecchia S (2003) Oligomerization of the  $\alpha_{1A}$ - and  $\alpha_{1B}$ -adrenergic receptor subtypes: potential implications in receptor internalization. *J Biol Chem* **278**: 40239–40251
- Terrillon S, Durroux T, Mouillac B, Breit A, Ayoub MA, Taulan M, Jockers R, Barberis C, Bouvier M (2003) Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. *Mol Endocrinol* **17**: 677–691
- Trettel F, Di Bartolomeo S, Lauro C, Catalano M, Ciotti TM, Limatola C (2003) Ligand-independent CXCR2 dimerization. *J Biol Chem* **278**: 40980–40988
- Wurch T, Matsumoto A, Pauwels PJ (2001) Agonist-independent and -dependent oligomerization of dopamine D<sub>2</sub> receptors by fusion to fluorescent proteins. *FEBS Lett* **507**: 109–113
- Xu J, He J, Castleberry AM, Balasubramanian S, Lau AG, Hall RA (2003) Heterodimerization of  $\alpha_{2A}$ - and  $\beta_1$ -adrenergic receptors. *J Biol Chem* **278**: 10770–10777
- Zhu CC, Cook LB, Hinkle PM (2002) Dimerization and phosphorylation of thyrotropin-releasing hormone receptors are modulated by agonist stimulation. *J Biol Chem* **277**: 28228–28237
- Zhu X, Wess J (1998) Truncated V2 vasopressin receptors as negative regulators of wild-type V2 receptor function. *Biochemistry* **37**: 15773–15784



Michel Bouvier & Sonia Terrillon